[go: up one dir, main page]

PH31676A - Compounds compositions and methods for binding bio-affecting subtances to surface membranes of bio-particles. - Google Patents

Compounds compositions and methods for binding bio-affecting subtances to surface membranes of bio-particles.

Info

Publication number
PH31676A
PH31676A PH45327A PH45327A PH31676A PH 31676 A PH31676 A PH 31676A PH 45327 A PH45327 A PH 45327A PH 45327 A PH45327 A PH 45327A PH 31676 A PH31676 A PH 31676A
Authority
PH
Philippines
Prior art keywords
bio
subtances
affecting
particles
methods
Prior art date
Application number
PH45327A
Other languages
English (en)
Inventor
Gregory A Kopia
David E Troutner
Paul K Horan
Kamleshkurmar A Sheth
Slezak Sue Ellen
Brian D Gray
Katharine A Muirhead
Nchia-En
Yu Zhizhou
Bruce D Jensen
Original Assignee
Zynaxis Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/884,432 external-priority patent/US5667764A/en
Application filed by Zynaxis Technologies Inc filed Critical Zynaxis Technologies Inc
Publication of PH31676A publication Critical patent/PH31676A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1258—Pills, tablets, lozenges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PH45327A 1991-11-27 1992-11-26 Compounds compositions and methods for binding bio-affecting subtances to surface membranes of bio-particles. PH31676A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79893691A 1991-11-27 1991-11-27
US07/884,432 US5667764A (en) 1988-05-02 1992-05-15 Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles

Publications (1)

Publication Number Publication Date
PH31676A true PH31676A (en) 1999-01-18

Family

ID=27122052

Family Applications (1)

Application Number Title Priority Date Filing Date
PH45327A PH31676A (en) 1991-11-27 1992-11-26 Compounds compositions and methods for binding bio-affecting subtances to surface membranes of bio-particles.

Country Status (10)

Country Link
EP (1) EP0643706A1 (fr)
JP (2) JP3682974B2 (fr)
CN (1) CN1074911A (fr)
AU (2) AU3221993A (fr)
CA (1) CA2124329C (fr)
IL (1) IL103874A0 (fr)
MX (1) MX9206844A (fr)
NZ (1) NZ245271A (fr)
PH (1) PH31676A (fr)
WO (1) WO1993011120A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100389223B1 (ko) * 1993-07-19 2003-10-08 안지오제네시스 테크놀로지스, 인코포레이티드 생체내통로관강을개방유지하기위한스텐트및이의제조방법
ATE255412T1 (de) * 1993-07-29 2003-12-15 Us Gov Health & Human Serv Verfahren zur behandlung atherosklerose oder restenose mit hilfe eines mikrotubulusstabilisators
US5480901A (en) * 1994-10-07 1996-01-02 Zynaxis, Inc. Method for reducing unwanted cellular adhesions
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US6004536A (en) * 1995-11-14 1999-12-21 Molecular Probes, Inc. Lipophilic cyanine dyes with enchanced aqueous solubilty
WO1997024459A1 (fr) * 1995-12-29 1997-07-10 Phanos Technologoes, Inc. Procede pour reduire les adherences cellulaires non desirees
US5871436A (en) * 1996-07-19 1999-02-16 Advanced Cardiovascular Systems, Inc. Radiation therapy method and device
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
ES2388248T3 (es) * 1997-03-31 2012-10-11 Boston Scientific Scimed Limited Forma de dosificación que comprende taxol en forma cristalina
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US7208011B2 (en) 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US7045305B1 (en) * 1998-04-08 2006-05-16 The Regents Of The University Of California Methods and reagents for targeting organic compounds to selected cellular locations
EP1174157B1 (fr) 1998-04-27 2005-06-29 Surmodics Inc. Revêtement destiné à libérer des agents bioactifs
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6333347B1 (en) 1999-01-29 2001-12-25 Angiotech Pharmaceuticals & Advanced Research Tech Intrapericardial delivery of anti-microtubule agents
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
NZ517188A (en) * 1999-08-23 2003-11-28 Angiogene Inc Radioactively coated device and method of making same for preventing restenosis
CO5261573A1 (es) 1999-11-19 2003-03-31 Novartis Ag Derivados de benzoxa y bezotiazol, compuesto y composicion farmaceutica que los contiene y proceso para la preparacion de la mencionada composicion
IT1319168B1 (it) * 2000-03-17 2003-09-26 Indena Spa Derivati di condensazione ad attivita' antitumorale, loro metodo dipreparazione e formulazioni che li contengono.
DE60133053T2 (de) 2000-10-16 2009-02-26 Conor Medsystems, Inc., Menlo Park Ausdehnbare medizinische Vorrichtung zur Abgabe eines nützlichen Agens
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US7056338B2 (en) 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
US7776529B2 (en) 2003-12-05 2010-08-17 Life Technologies Corporation Methine-substituted cyanine dye compounds
WO2005099787A1 (fr) 2004-04-06 2005-10-27 Surmodics, Inc. Compositions de revetement par agents bioactifs
USD516723S1 (en) 2004-07-06 2006-03-07 Conor Medsystems, Inc. Stent wall structure
WO2006054904A2 (fr) 2004-11-22 2006-05-26 Ge Healthcare As Agents de contraste
US9050393B2 (en) 2005-02-08 2015-06-09 Bruce N. Saffran Medical devices and methods for modulation of physiology using device-based surface chemistry
EP1885718B1 (fr) 2005-05-11 2017-03-15 Life Technologies Corporation Composes chimiques fluorescents possedant une selectivite elevee pour l'adn double brin, et procedes d'utilisation
US8114429B2 (en) 2008-09-15 2012-02-14 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8257722B2 (en) 2008-09-15 2012-09-04 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US9198968B2 (en) 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
EP3075777A4 (fr) 2013-11-26 2017-08-02 Sumitomo Chemical Company Limited Composition de caoutchouc et auxiliaire de vulcanisation
US10525171B2 (en) 2014-01-24 2020-01-07 The Spectranetics Corporation Coatings for medical devices
EP3101012A1 (fr) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft Nouveaux composés de chélate de gadolinium pour une utilisation dans l'imagerie par résonance magnétique
JP7034160B2 (ja) 2016-11-28 2022-03-11 バイエル・ファルマ・アクティエンゲゼルシャフト 磁気共鳴画像法に使用するための高緩和度ガドリニウムキレート化合物
CN113164628A (zh) 2018-11-23 2021-07-23 拜耳股份有限公司 造影介质制剂及其制备方法
JP7423888B2 (ja) * 2019-11-22 2024-01-30 株式会社同仁化学研究所 脂質二分子膜染色用色素及びそれを用いた脂質二分子膜の染色方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523965A (en) * 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
DE3170134D1 (en) * 1980-09-02 1985-05-30 Fuji Photo Film Co Ltd Method for immunochemical measurement
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4751219A (en) * 1985-02-05 1988-06-14 Nederlandse Centrale Organisatie Voor Toegepast-Natuur-Wetenschappelijk Onderzoek Synthetic glycolipides, a process for the preparation thereof and several uses for these synthetic glycolipides
US4762701A (en) * 1986-10-31 1988-08-09 Smithkline Beckman Corporation In vivo cellular tracking
US4783401A (en) * 1986-10-31 1988-11-08 Smithkline Beckman Corporation Viable cell labelling
US4906749A (en) * 1987-06-30 1990-03-06 Viomedics Inc. Cyclic anhydride derivatives of chromophors
WO1989006654A1 (fr) * 1988-01-19 1989-07-27 Board Of Regents, The University Of Texas System Glycosides, compositions liposomiques a base de ces composes et procedes d'utilisation
ATE145337T1 (de) * 1988-05-02 1996-12-15 Phanos Tech Inc Verbindungen, zusammensetzungen und verfahren zum binden von bio-affektions-substanzen an oberflächenmembranen von bioteilchen
US5149794A (en) * 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting

Also Published As

Publication number Publication date
WO1993011120A1 (fr) 1993-06-10
JP2003026657A (ja) 2003-01-29
NZ245271A (en) 1996-03-26
MX9206844A (es) 1993-07-01
JP3682974B2 (ja) 2005-08-17
JP4095847B2 (ja) 2008-06-04
JPH08502719A (ja) 1996-03-26
EP0643706A4 (fr) 1994-12-27
AU1991497A (en) 1997-07-10
EP0643706A1 (fr) 1995-03-22
CA2124329A1 (fr) 1993-06-10
AU3221993A (en) 1993-06-28
CA2124329C (fr) 2008-11-18
CN1074911A (zh) 1993-08-04
IL103874A0 (en) 1993-04-04

Similar Documents

Publication Publication Date Title
PH31676A (en) Compounds compositions and methods for binding bio-affecting subtances to surface membranes of bio-particles.
EP0371584A3 (en) Unpleasant taste masking compositions and methods for preparing same
GB9101659D0 (en) Compositions of matter
GB2219937B (en) Composition for desorbing bacteria
SG48141A1 (en) Composition of difluoromethane and tetrafluoroeth- ane
ZA929883B (en) Pharmaceutical composition and process for the preparation thereof
GB9108369D0 (en) Compositions of matter
EP0448128A3 (en) Cembrane-type diterpene compounds for use in the production of compositions containing histamine release inhibitors
HU895450D0 (en) Process for the preparation of antiflatulent pharmaceutical composition containing activated polydimethylsiloxane in solid dispersion
EP0437367A3 (en) Compositions and methods for inhibiting osteoclast cellular adhesion to bone
ZA929179B (en) Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles.
JPS6426633A (en) Alkoxylated polyester and its production and composition containing said polyester as effective component
IL105349A0 (en) Pharmaceutical compositions containing beta-carbolines,methods for the preparation thereof and compounds for use in the preparation thereof
GB9200519D0 (en) Composition of matter
EP0508119A3 (en) Novel process for the preparation of amine-terminated compounds
GB2195247B (en) Transdermal laminated pharmaceutical compositions having prolonged effect and process for the preparation thereof
DE69304982D1 (de) Buchbindungsverfahren und Klebstoffzusammensetzung zur Durchführung des Verfahrens
IE891338L (en) Compounds for binding bio-affecting substances to surface¹membranes of bio-particles
ZA921040B (en) Process for the preparation of 4-alkylsulfonyl-1-alkyl-2-chlorobenzenes and similar compounds
ZA922354B (en) Pharmaceutical composition and process for the preparation thereof
GB8712396D0 (en) Composition of matter
IL72451A (en) Pharmaceutical antitumor composition containing rhizoxin and method for the preparation thereof
GB2232981B (en) Process for the preparation of water soluble primyoin and its components and pharmaceutical compositions containing them
LTIP164A (en) Composition of extract
PL289404A1 (en) Method of isolating alkaloids as individual compounds or in groups from materials of plant origin